North America
Tags: Canada, Life SciencesBy Richard Y. Cheung, Ph.D., Toronto, Fasken Martineau DuMoulin
Due to concerns about the growing percentage of the health care budget allotted to drug spending in Canada and the relative drug prices in Canada compared to other developed countries, the Canadian government is proposing changes to the way in which prices for patented drugs are regulated …
Read or download the full article below.
Latest Updates
Related Articles
Related Articles by Jurisdiction
A 'return' to private practice
Three experienced Asia-based lawyers spoke to Tim Gilkison about their 'return' to private practice, and how to make a successful transition ...
Does your non-competition clause really protect you?
Or does it merely offer the illusion of protection? What you need to know about the validity and enforceability of a non-competition clause.
Corporate Parent Liability: Litigation Risks for Resource Companies
Traditionally, parent companies have been considered legally distinct entities and thus immune from the actions of their subsidiaries, a concept described as the “corporate veil”. This position is now being challenged ...
Latest Articles
